Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by significantly improving long-term outcomes across multiple malignancies. Despite their benefits, ICIs can lead to immune-related adverse events, including rare but severe cardiovascular ... ...

请注册登录后继续浏览